预约演示
更新于：2026-06-15
Toripalimab
特瑞普利单抗
更新于：2026-06-15
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2018-12-17), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (美国)、突破性疗法 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)、附条件批准 (中国)、优先审评 (新加坡)、孤儿药 (澳大利亚)、快速通道 (美国) |
登录后查看时间轴
结构/序列
Sequence Code 453640391L
来源: *****
Sequence Code 524455911H
来源: *****
关联
776
项与 特瑞普利单抗 相关的临床试验NCT05479045
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
NCT07619235
A Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer
NCT07358689
Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist (Diphenhydramine) in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer: A Single-center, Randomized Controlled Phase II Clinical Trial
100 项与 特瑞普利单抗 相关的临床结果
登录后查看更多信息
100 项与 特瑞普利单抗 相关的转化医学
登录后查看更多信息
100 项与 特瑞普利单抗 相关的专利（医药）
登录后查看更多信息
674
项与 特瑞普利单抗 相关的文献（医药）2026-09-01JOURNAL OF INORGANIC BIOCHEMISTRY
Copper (I) nicotinate complex potentiates chemotherapy-induced apoptosis in HCC-1806 triple negative breast cancer cells: An in vitro study
Article
作者: Abdel-Mohsen, Mohamed A ; Helal, Marihan A ; Toson, Elshahat A
Triple negative breast cancer (TNBC) remains a clinically challenging subtype because it lacks established molecular targets and often depends on cytotoxic chemotherapy. Although doxorubicin (DOX) and mTOR inhibitors such as Torin1 (TOR) exhibit antitumor activity, their clinical use may be constrained by toxicity and resistance. Copper (I) Nicotinate Complex (CNC) has emerged as promising candidates due to their superoxide dismutase (SOD) -mimicking and cytoprotective properties. This study aimed to evaluate the potential effect of CNC combined with DOX or TOR to enhance cytotoxicity against HCC-1806 cells while reducing individual drug dosages. Cell viability was assessed via MTT assay. Drug interactions were analyzed by combination index methodology. Mechanistic responses were evaluated using Annexin V/PI flow cytometry, cell cycle analysis, Comet assay, and biochemical quantification of Caspase-3, Survivin, pCHK1ser317, and SOD activity. CNC containing combinations enhanced cytotoxic responses relative to selected single-agent conditions, with ratio-dependent additive or synergistic interactions. Combination treatments increased apoptotic populations, altered cell cycle progression with enrichment of sub G0-G2/M fractions, and elevated DNA damage associated markers, including comet tail moment and pCHK1ser317. CNC inclusive regimens also increased caspase-3 activity and reduced survivin expression. Increased SOD activity indicated modulation of oxidative stress related responses. Exploratory analysis showed treatment-associated changes in PD-1 expression. In conclusion, these findings provide preliminary in vitro evidence that CNC may potentiate selected anticancer responses of DOX or TOR in HCC-1806 cells through apoptosis-associated, cell cycle, and DNA damage-related mechanisms. Further validation in additional TNBC models and in vivo systems is required.
2026-07-01FOOD CHEMISTRY
Molecularly imprinted metal-organic framework-based potentiometric sensor for sensitive detection of torsemide in dietary supplements and milk
Article
作者: Elghobashy, Mohamed R ; Heragy, Manar Omar ; Moustafa, Azza Aziz M ; Tantawy, Mahmoud A ; El-Mosallamy, Sally S
Torsemide (TOR) is increasingly misused in weight-loss products and livestock practices, posing significant health risks to consumers and athletes. In this study, novel potentiometric sensor integrating molecularly imprinted polymer (MIP) with MIL-101 (Cr) metal-organic framework was developed for selective and sensitive detection of TOR. The fabricated TOR-MIL/MIP sensor exhibited near-Nernstian slope of 56.3 mV/decade over wide linear response range of 1.0 × 10-7-1.0 × 10-3 M with LOD of 6.3 × 10-8 M. High porosity of MIL-101(Cr) greatly enhanced charge-transfer efficiency at electrode interface, facilitating ion-to-electron transduction and improving potential stability. Selectivity of sensor against common pharmaceutical adulterants was tested, and the sensor was used to analyze TOR in several dietary supplement matrices. Additionally, raw milk sample was fortified with TOR to assess method's applicability in food safety monitoring. Results showed recoveries ranging from 97.91%-104.53% and RSDs below 1.7%. These findings affirm sensor's precision and suitability for routine screening of TOR adulteration in both dietary supplements and food matrices.
2026-06-01EUROPEAN JOURNAL OF CANCER
Gastric cancer: French intergroup clinical practice guidelines for diagnosis, staging, treatment and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACHBPT, RENAPE, SNFCP)
Review
作者: Ducreux, Michel ; Abdelghani, Meher Ben ; Dubreuil, Olivier ; Jary, Marine ; Renaud, Florence ; Palle, Juliette ; Zaanan, Aziz ; Gagniere, Johan ; Mariani, Antoine ; Buecher, Bruno ; Barret, Maximilien ; Chapelle, Nicolas ; Durand-Labrunie, Jerome ; Palmieri, Lola-Jade ; Bouché, Olivier ; Fares, Nadim
INTRODUCTION:
The updated edition of the French intergroup guidelines for the management of patients with gastric and gastroesophageal junction adenocarcinoma is a collaborative work of several national medical societies, and available on the website of the French Society of Gastroenterology (SNFGE) (www.tncd.org).
METHODS:
The recommendations are graded into three categories (A, B, and C), based on the level of scientific evidence published until January 2026.
RESULTS:
Initial staging and risk assessment should include physical evaluation, endoscopy and computed tomography-scan of the thorax, abdomen, and pelvis. For resectable disease, endoscopic ultrasonography can be used for T and N staging, while laparoscopic exploration may be performed to exclude occult peritoneal metastases, especially for cT3/cT4 and poorly cohesive tumors. Endoscopic or surgical resection alone is appropriate for very early cT1N0 tumors. For locally advanced disease ≥cT2 and/or cN + , the perioperative FLOT chemotherapy is recommended as the standard of care. Recently, the addition of durvalumab to perioperative FLOT followed by durvalumab for 10 months as maintenance therapy was associated with a significant improvement of survival. For metastatic disease, the first-line chemotherapy is based on platinum-fluoropyrimidine combination. The addition of targeted therapy and/or immunotherapy to doublet chemotherapy depends on the tumor biomarker profile, including HER2 (trastuzumab), claudin18.2 (zolbetuximab), PD-L1 and dMMR/MSI phenotype (anti-PD1 monoclonal antibodies). The addition of docetaxel, based on the triplet TFOX regimen may be considered for selected patients with biomarker-negative tumors. Resection of primary tumor and metastases cannot be recommended but may be considered on an individual basis in highly selected patients with oligometastatic disease who respond to systemic treatment. Various drugs are indicated beyond first-line of treatment, including trastuzumab-deruxtecan for HER2-positive tumors.
CONCLUSION:
These national guidelines on gastric cancer are intended to facilitate decision-making in daily clinical practice. These recommendations are subject to ongoing review. Each individual case should be discussed within a multidisciplinary team.
3,890
项与 特瑞普利单抗 相关的新闻（医药）2026-06-14
·谈医说药
100 项与 特瑞普利单抗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| HER2阳性尿路上皮癌 | 中国 | 2026-05-19 | |
| 转移性黑色素瘤 | 中国 | 2025-04-22 | |
| 不可切除的黑色素瘤 | 中国 | 2025-04-22 | |
| 晚期肝细胞癌 | 中国 | 2025-03-18 | |
| 转移性食管鳞状细胞癌 | 欧盟 | 2024-09-19 | |
| 转移性食管鳞状细胞癌 | 冰岛 | 2024-09-19 | |
| 转移性食管鳞状细胞癌 | 列支敦士登 | 2024-09-19 | |
| 转移性食管鳞状细胞癌 | 挪威 | 2024-09-19 | |
| 鼻咽肿瘤 | 欧盟 | 2024-09-19 | |
| 鼻咽肿瘤 | 冰岛 | 2024-09-19 | |
| 鼻咽肿瘤 | 列支敦士登 | 2024-09-19 | |
| 鼻咽肿瘤 | 挪威 | 2024-09-19 | |
| 复发性食管鳞状细胞癌 | 欧盟 | 2024-09-19 | |
| 复发性食管鳞状细胞癌 | 冰岛 | 2024-09-19 | |
| 复发性食管鳞状细胞癌 | 列支敦士登 | 2024-09-19 | |
| 复发性食管鳞状细胞癌 | 挪威 | 2024-09-19 | |
| 不能切除的食管鳞状细胞癌 | 欧盟 | 2024-09-19 | |
| 不能切除的食管鳞状细胞癌 | 冰岛 | 2024-09-19 | |
| 不能切除的食管鳞状细胞癌 | 列支敦士登 | 2024-09-19 | |
| 不能切除的食管鳞状细胞癌 | 挪威 | 2024-09-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肿瘤 | 申请上市 | 加拿大 | 2024-12-01 | |
| 复发性鼻咽癌 | 申请上市 | 欧盟 | 2022-11-14 | |
| 复发性非鳞状非小细胞肺癌 | 临床3期 | 中国 | 2024-04-03 | |
| 难治性经典霍奇金淋巴瘤 | 临床3期 | 中国 | 2023-12-28 | |
| 局限期小细胞肺癌 | 临床3期 | 美国 | 2023-11-15 | |
| 局限期小细胞肺癌 | 临床3期 | 中国 | 2023-11-15 | |
| 局限期小细胞肺癌 | 临床3期 | 比利时 | 2023-11-15 | |
| 局限期小细胞肺癌 | 临床3期 | 法国 | 2023-11-15 | |
| 局限期小细胞肺癌 | 临床3期 | 德国 | 2023-11-15 | |
| 局限期小细胞肺癌 | 临床3期 | 意大利 | 2023-11-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 70 | 醖壓夢蓋願鏇糧夢襯遞(鬱襯蓋積鏇鑰繭獵鏇範) = 顧夢齋窪蓋夢鑰鑰餘膚 鏇鑰窪製壓積願鬱選鑰 (鬱鏇築獵顧膚窪繭憲網, 18.9 ~ 42.7) 更多 | 积极 | 2026-05-29 | |||
临床2期 | 局部晚期肝细胞癌 一线 | 72 | FOLFOX-HAIC plus Toripalimab | 製廠廠鏇構醖艱廠繭夢(衊繭鹹鏇膚願艱範壓糧) = 築鹹觸鏇鏇製衊選選製 築選網網繭艱網鏇鏇鬱 (遞餘築遞餘築獵製餘簾 ) 更多 | 积极 | 2026-05-29 | |
FOLFOX-HAIC plus Sorafenib | 製廠廠鏇構醖艱廠繭夢(衊繭鹹鏇膚願艱範壓糧) = 鬱夢鏇鹽鹹艱鏇簾網範 築選網網繭艱網鏇鏇鬱 (遞餘築遞餘築獵製餘簾 ) 更多 | ||||||
临床2期 | 30 | Toripalimab plus GP regimen | 醖蓋鏇遞糧鬱餘築選膚(遞夢構網壓築壓製範廠) = 選構襯廠壓壓觸獵淵網 選憲鑰糧觸觸簾糧築憲 (願糧鹽繭衊製鏇鹽鏇鏇 ) 更多 | 积极 | 2026-05-29 | ||
临床2期 | 18 | 願製襯艱糧醖鏇顧壓獵(選膚鬱構窪觸願築窪選) = 範願蓋淵膚網網夢窪鬱 願鬱淵網夢窪廠醖襯廠 (夢窪窪繭壓衊鹽顧憲鬱 ) 更多 | 积极 | 2026-05-29 | |||
临床2期 | 肾盂和输尿管尿路上皮癌 HER2 1+ | HER2 2+ | HER2 | 9 | 齋選廠築顧醖觸繭範齋(襯製醖願襯糧網廠壓窪) = 壓衊廠願製網遞醖醖觸 鏇製餘獵膚繭鬱餘窪憲 (範衊鏇選衊蓋獵觸艱憲 ) 更多 | 积极 | 2026-05-29 | ||
临床2期 | 8 | 鑰淵鏇願鏇築憲鏇鹹鏇(願壓憲鹽鏇壓襯鹹簾網) = 製蓋選鏇鬱鹹醖艱鑰鹹 繭繭襯鬱夢願廠廠膚憲 (夢鏇衊鹽膚選遞鑰艱醖 ) 更多 | 积极 | 2026-05-29 | |||
临床2期 | 27 | toripalimab +chemotherapy | 壓醖膚鹽鏇鑰獵獵襯窪(壓鑰齋壓壓艱夢廠繭鬱) = 淵衊蓋淵範壓窪壓窪構 糧齋獵窪襯鑰蓋醖餘窪 (壓顧顧襯積鹽鑰淵築襯 ) 更多 | 积极 | 2026-05-29 | ||
toripalimab +chemotherapy (Excluding patients with pretreatment tracheostomy) | 壓醖膚鹽鏇鑰獵獵襯窪(壓鑰齋壓壓艱夢廠繭鬱) = 衊構選憲衊簾淵艱遞壓 糧齋獵窪襯鑰蓋醖餘窪 (壓顧顧襯積鹽鑰淵築襯 ) 更多 | ||||||
临床1/2期 | 45 | Toripalimab+Pemetrexed | 蓋構衊願獵積糧顧糧簾(膚觸鹽積齋窪顧餘廠艱) = 繭製蓋鏇觸廠築鹹壓憲 鑰蓋糧願襯壓衊蓋願範 (構積製夢築襯築遞範襯 ) 更多 | 积极 | 2026-05-29 | ||
临床2期 | - | 20 | 繭構繭鏇廠構淵網憲獵(齋蓋窪蓋齋夢願範壓醖) = 窪製壓壓鹹鹹選網鑰獵 憲窪醖壓糧鬱鹽鹽淵顧 (顧範積獵齋淵鏇鏇艱鹹 ) 更多 | 积极 | 2026-05-29 | ||
临床2期 | 19 | 淵憲淵鏇壓夢蓋鬱鑰糧(齋糧憲壓築窪願簾築網) = 膚壓糧簾艱齋簾淵齋選 膚鬱鑰鬱鑰淵簾膚鹽淵 (鏇願構遞鏇鏇獵鹹憲壓, 2.6 ~ 8.8) 更多 | 积极 | 2026-05-29 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用